Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Permanent Vision Loss in Late Giant Cell Arteritis

Kimberly Retzlaff  |  Issue: October 2018  |  October 18, 2018

Specifically, Dr. Liozon recommends physicians consider the following:

  • Regularly ask these patients if they have cranial or ear, nose, and throat symptoms suggesting GCA;
  • If they do, perform a careful examination of the temporal arteries, and perform a search for a bruit over axillary/humeral arteries. If any abnormalities are discovered, perform additional workups; and
  • For any otherwise unexplained, persisting acute phase response in a patient with controlled or recovered PMR, order imaging of the patient’s aorta.

Dr. Liozon notes, “18F-FDG PET/CT is an effective imaging modality for detecting silent aortitis. Since [a] PET/CT scan often discloses the presence of large vessel vasculitis (LVV) in PMR patients, careful selection of those who really need it is crucial.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers also note that a “questionable female predominance was the only distinguishing feature of PMR or peripheral arthritis evolving into GCA,” but this should not necessarily affect practice.

“Although we found a strong association between female sex and the risk of late GCA, this finding may be inconsistent since the control cohort of PMR patients recruited in internal medicine was highly biased toward male patients,” Dr. Liozon says. “Accordingly, this should have no practical implication for clinicians who care for PMR patients.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. ­Liozon had the following advice for discussing risks with patients: “Both [general practitioners] and rheumatologists should educate their PMR patients about the main cranial symptoms and signs of GCA, while stressing the low frequency of such an occurrence so as not to worry them unnecessarily. No additional testing is needed, since both PMR and GCA flares are best diagnosed upon raised ESR and CRP, along with a complete blood count.”


Kimberly J. Retzlaff is a freelance medical journalist based in Denver.

References

  1. Liozon E, de Boysson H, Dalmay F, et al. Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: A retrospective case-control study. J Rheumatol. 2018 Mar;45(5):678–685.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsVasculitis Tagged with:peripheral arthritisPolymyalgia Rheumaticavision lossvisual loss

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Case Report: Giant Cell Arteritis-Related Stroke

    September 10, 2023

    Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

    Updates on Giant Cell Arteritis

    March 19, 2018

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

    Experts Discuss Proposed Giant Cell Arteritis Risk Tool

    April 26, 2018

    A proposed model to predict the risk of giant cell arteritis (GCA) prior to a temporal artery biopsy could help triage patients and guide decision making about the need for biopsy or monitoring (see Figure 1). There’s no specific biomarker for GCA, and GCA can be a “diagnostic conundrum, especially when it presents in an…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences